Pediatric Reactive Airway Disease
- Author: Eric S Chin, MD; Chief Editor: Kirsten A Bechtel, MD more...
Not all children who wheeze have asthma. Most children younger than 3 years who wheeze are not predisposed to asthma. Only 30% of infants who wheeze go on to develop asthma. Reactive airway disease has a large differential diagnosis and must not be confused with asthma.
To establish the diagnosis of asthma, certain criteria should be met :
- At least 5 years of age
- Episodic symptoms of airflow obstruction or airway hyperresponsiveness
- Reversible airflow obstruction of at least 10% of predicted forced expiratory volume in one second (FEV1) after use of short-acting beta2-agonist
- Alternative diagnoses have been excluded
On June 25, 2009, The American Thoracic Society and the European Respiratory Society jointly released new official standards on asthma evaluation for clinical trials and practice. The Medscape Medical News article, New Guidelines Issued for Asthma Assessment, has a more detailed discussion.
Numerous environmental stimuli induce an allergen-antibody interaction, causing a release of mediators that create airway inflammation. Airway inflammation is the primary factor responsible for smooth muscle hyperresponsiveness, edema, and increased mucous production. A complex interaction occurs between inflammatory cells and airway epithelium. Mast cells, eosinophils and lymphocytes secrete mediators include histamine, tryptase, heparin, leukotrienes, platelet-activating factor, cytokines, interleukins, and tumor necrosis factor and create an environment toxic to respiratory epithelial cells by causing edema, mucous secretion, bronchospasm and increased work of breathing.
Speculation exists that all infants are born with highly responsive airways. Increased immunoglobulin E (IgE) levels have been found in those younger than 2 years. A decrease in airway responsiveness may be associated with environmental allergens, viral respiratory diseases, and hereditary factors. In children younger than 3 years, the intrapulmonary airways are so small that any lower airway infection results in diminished airway function. Other anatomical factors, such as poor collateral ventilation, decreased elastic recoil pressure, and a partially developed diaphragm, may predispose the very young child to respiratory compromise.
Rhinovirus infections are an important contributor to asthma exacerbations in children. Hence, therapies against rhinovirus might reduce the risk of severe exacerbations. Fever and bronchospasm are not associated with a more severe clinical course. In fact, fever as a response to infection may have a beneficial effect and can be seen as a good prognostic indicator. Recently, it has been hypothesized that severe infection with Respiratory Syncytial Virus (RSV) may be a marker of a predisposing factor for asthma.
There are several theories as to prevention of bronchospasm and asthma in children. The hygiene hypothesis suggests that early exposure to infections and allergens might protect children from developing asthma later in life because of improved immune system.
Breastfeeding might protect children younger than 24 months of age against recurrent wheezing. The cytokine, TGF-B1, in human milk may have both suppression and enhancement functions in the immune reaction.
Exposure to maternal environmental tobacco smoke during pregnancy or the first year appears to predispose children to reactive airway disease.
Current research on the genetic basis for the pathogenesis of asthma may lead to new diagnostic and preventive treatments. The ADAM33 gene on the short arm of chromosome 20 is hypothesized as being important in the development and pathogenesis of asthma.
Pediatric asthma is a chronic, multifactorial, lower airway disease that affects 5-15% of children (2.7 million children in the United States alone). In the United States, approximately one half of all ED and clinic visits for asthma are children younger than 18 years. ED visits peak in the fall while school holidays disrupt the spread of infections resulting in a subsequent decrease in ED visits and hospitalizations. Status asthmaticus appears to be on the rise; several retrospective studies reflect an increase in hospital admissions, particularly in those younger than 4 years. Fewer hospital and ED visits occur in children using inhaled corticosteroid therapy.
Asthma prevalence appears to be increasing worldwide. Air pollutants may play a role in the prevalence increase. Higher prevalence occurs in poverty stricken urban areas where children are less likely to have routine doctor visits and access to the availability of medications.
A correlation may exist between high levels of exposure to cockroach allergen and the frequency of asthma-related health problems in inner-city children. Homes in poverty areas were more likely to have high cockroach allergen levels. Asthma may develop in children from early exposure to cockroach allergen. An association may exist between obesity and childhood asthma. Increased resistin, an adipokine produced by adipose tissue, may play a negative predictive role in asthma.
An algorithm has been developed to determine the risk factors for developing persistent asthma symptoms among children younger than 3 years of age who had 4 or more episodes of wheezing during the previous year. The Asthma Predictive Index included either (1) one of the following: parental history of asthma, a physician diagnosis of atopic dermatitis, or evidence of sensitization to aeroallergens; or (2) two of the following: evidence of sensitization to foods, ≥4% peripheral blood eosinophilia, or wheezing apart from colds.
Worldwide, the prevalence of asthma is increasing. Asthma is found to be more common in Western countries than in developing countries. Asthma is more prevalent in English-speaking countries. Prevalence increases as a developing country becomes more Westernized and urbanized.
See the list below:
One third of all children younger than 18 years are significantly affected.
Reactive airway disease accounts for 13 million health care visits annually in the United States and 200,000 hospitalizations for which approximately $1.8 billion is spent annually.
Mortality rates are increasing despite new pharmacologist advances.
European Respiratory Society (ERS) and American Thoracic Society (ATS), created a task force to evaluate and provide management recommendations for severe or therapy-resistant asthma, recognized as a major unmet need. Severe asthma is defined as requiring treatment with high-dose inhaler plus a second controller and-or systemic corticosteroids to prevent it from becoming "uncontrolled" or that remains "uncontrolled" despite this therapy. Current research based on phenotyping (epidemiology, pathogenesis, pathobiology, structure and physiology) to allow better diagnosis and targeted treatment. 
Reactive airway disease is more common in black and Hispanic children; hospitalization rates in African Americans are 4 times greater than in the white population. A correlation may exist between high levels of exposure to cockroach allergen and the frequency of asthma-related health problems in inner-city children.
No correlation exists between education levels from a retrospective review.
The male-to-female ratio is 1.5:1.
The peak prevalence of asthma is in those aged 6-11 years.
[Guideline] Expert panel commissioned by the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee(CC), coordinated by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health. The Expert Panel Report 3 (EPR-3) Full Report 2007: Guidelines for the Diagnosis and Management of Asthma. August 28, 2007. [Full Text].
[Guideline] Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/european Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009 Jul 1. 180(1):59-99. [Medline].
Szefler SJ. Advances in pediatric asthma in 2007. J Allergy Clin Immunol. 2008 Mar. 121(3):614-9. [Medline].
Sahib El-Radhi A, Patel S. The clinical course of childhood asthma in association with fever. Clin Pediatr (Phila). 2009 Jul. 48(6):627-31. [Medline].
Lotz MT, Moore ML, Peebles RS Jr. Respiratory syncytial virus and reactive airway disease. Curr Top Microbiol Immunol. 2013. 372:105-18. [Medline].
Rosenstreich DL, Eggleston P, Kattan M, et al. The role of cockroach allergy and exposure to cockroach allergen in causing morbidity among inner-city children with asthma. N Engl J Med. 1997 May 8. 336(19):1356-63. [Medline].
Litonjua AA, Carey VJ, Burge HA, et al. Exposure to cockroach allergen in the home is associated with incident doctor-diagnosed asthma and recurrent wheezing. J Allergy Clin Immunol. 2001 Jan. 107(1):41-7. [Medline].
Kim KW, Shin YH, Lee KE, Kim ES, Sohn MH, Kim KE. Relationship between adipokines and manifestations of childhood asthma. Pediatr Allergy Immunol. 2008 Sep. 19(6):535-40. [Medline].
Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000 Oct. 162(4 Pt 1):1403-6. [Medline]. [Full Text].
[Guideline] Kian Fan Chung, Sally E. Wenzel, Jan L. Brozek , Andrew Bush, Mario Castro. International ERS/ATS guidelines ondefinition, evaluation and treatment of severe asthma. Eur Respir J. April 2014. 43:343-373. [Medline]. [Full Text].
Tagiyeva N, Devereux G, Fielding S, Turner S, Douglas G. Outcomes of Childhood Asthma and Wheezy Bronchitis. A 50-Year Cohort Study. American journal of respiratory and critical care medicine. January 1, 2016. 193 (1):23-30. [Medline].
Federico MJ, Wamboldt FS, Carter R, Mansell A, Wamboldt MZ. History of serious asthma exacerbations should be included in guidelines of asthma severity. J Allergy Clin Immunol. 2007 Jan. 119(1):50-6. [Medline].
Stewart LJ. Pediatric asthma. Prim Care. 2008 Mar. 35(1):25-40, vi. [Medline].
Hederos CA, Janson S, Andersson H, Hedlin G. Chest X-ray investigation in newly discovered asthma. Pediatr Allergy Immunol. 2004 Apr. 15(2):163-5. [Medline].
Hsu KH, Jenkins DE, Hsi BP, et al. Ventilatory functions of normal children and young adults--Mexican- American, white, and black. II. Wright peak flowmeter. J Pediatr. 1979 Aug. 95(2):192-6. [Medline].
Williams AM, Abramo TJ, Shah MV, et al. Safety and clinical findings of BiPAP utilization in children 20 kg or less for asthma exacerbations. Intensive Care Med. 2011 Aug. 37(8):1338-43. [Medline].
Kaashmiri M, Shepard J, Goodman B, Lincourt WR, Trivedi R, Ellsworth A, et al. Repeat dosing of albuterol via metered-dose inhaler in infants with acute obstructive airway disease: a randomized controlled safety trial. Pediatr Emerg Care. 2010 Mar. 26(3):197-202. [Medline].
Andrews AL, Teufel RJ 2nd, Basco WT Jr, Simpson KN. A cost-effectiveness analysis of inhaled corticosteroid delivery for children with asthma in the emergency department. J Pediatr. 2012 Nov. 161(5):903-7. [Medline].
Andrews AL, Wong KA, Heine D, Scott Russell W. A cost-effectiveness analysis of dexamethasone versus prednisone in pediatric acute asthma exacerbations. Acad Emerg Med. 2012 Aug. 19(8):943-8. [Medline].
SJ Teach et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. Journal of Allergy and Clinical Immunology. December 2015. Volume 136, Issue 6:1476–1485. [Full Text].
Chong J, Haran C, Chauhan BF, Asher I. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. The Cochrane database of systematic reviews. January 1, 2015. 7:[Medline].
Chauhan BF, Chartrand C, Ni Chroinin M, Milan SJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. The Cochrane database of systematic reviews. January 1, 2015. 11:[Medline].
Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. APR 2010. Issue 4:[Full Text].
Stanford R, et al. Comparative clinical and economic outcomes in children with asthma initiating eitherfluticasone propionate plus salmeterol or inhaled corticosteroids plus montelukast. Ann Allergy Asthma Immunol. Nov 2009. 103(5):62. [Full Text].
Nino G, Grunstein MM. Current concepts on the use of glucocorticosteroids and beta-2-adrenoreceptor agonists to treat childhood asthma. Curr Opin Pediatr. 2010 Feb 15. [Medline].
Childhood Asthma Treatment: Not One-Size-Fits-All. National Heart, Lung, and Blood Institute (NHLBI). March 2,2010. Available at http://www.nih.gov/news/health/mar2010/nhlbi-02.htm.
Massanari M, Milgrom H, Pollard S, Maykut RJ, Kianifard F, Fowler-Taylor A, et al. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. Clin Pediatr (Phila). 2009 Oct. 48(8):859-65. [Medline].
Sandstrom T. Omalizumab in the management of patients with allergic (IgE-mediated) asthma. Journal of Asthma and Allergy. May 2009. 2:49-62. [Full Text].
Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol. 2009 Dec. 124(6):1210-6. [Medline].
Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair). US Department of Health and Human Services/FDA. July 2009. Available at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm172218.htm.
Schramm CM, Carroll CL. Advances in treating acute asthma exacerbations in children. Curr Opin Pediatr. 2009 Jun. 21(3):326-32. [Medline].
Zeiger RS, Mauger D, Bacharier LB, Guilbert TW, Martinez FD, Lemanske RF Jr, et al. Daily or intermittent budesonide in preschool children with recurrent wheezing. N Engl J Med. 2011 Nov 24. 365(21):1990-2001. [Medline].
Morse RB, Hall M, Fieldston ES, McGwire G, Anspacher M, Sills MR, et al. Hospital-level compliance with asthma care quality measures at children's hospitals and subsequent asthma-related outcomes. JAMA. 2011 Oct 5. 306(13):1454-60. [Medline].
Mireku N, Wang Y, Ager J, Reddy RC, Baptist AP. Changes in weather and the effects on pediatric asthma exacerbations. Ann Allergy Asthma Immunol. 2009 Sep. 103(3):220-4. [Medline].
Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007 Jan. 119(1):64-72. [Medline].
Li P, Guttmann A. Recent innovations to improve asthma outcomes in vulnerable children. Curr Opin Pediatr. 2009 Dec. 21(6):783-8. [Medline].
Nuorti JP, Whitney CG. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 Dec 10. 59:1-18. [Medline].
Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010 Aug 6. 59:1-62. [Medline].
Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2012-2013. Pediatrics. 2012 Oct. 130(4):780-92. [Medline].
US Food and Drug Administration. Asthmatx, Inc. Alair Bronchial Thermoplasty System - P080032. 2010. Available at http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/recently-approveddevices/ucm212594.htm.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18. 380(9842):651-9. [Medline].
J. Bernstein et. al. Once-Daily Tiotropium Respimat Added-On to Inhaled Corticosteroids in a 1-Year Study in Adolescent Patients With Symptomatic Asthma Is Efficacious and Well Tolerated. Chest Journal. October 29, 2014. October 2014, Vol 146, No. 4_MeetingAbstracts:[Full Text].
Amirav I, Newhouse MT. Metered-dose inhaler accessory devices in acute asthma: efficacy and comparison with nebulizers: a literature review. Arch Pediatr Adolesc Med. 1997 Sep. 151(9):876-82. [Medline].
Apter AJ, Szefler SJ. Advances in adult and pediatric asthma. J Allergy Clin Immunol. 2004 Mar. 113(3):407-14. [Medline].
Baren JM, Zorc JJ. Contemporary approach to the emergency department management of pediatric asthma. Emerg Med Clin North Am. 2002 Feb. 20(1):115-38. [Medline].
Beasley R, Crane J, Lai CK, Pearce N. Prevalence and etiology of asthma. J Allergy Clin Immunol. 2000 Feb. 105(2 Pt 2):S466-72. [Medline].
Becker A, Watson W, Ferguson A, et al. The Canadian asthma primary prevention study: outcomes at 2 years of age. J Allergy Clin Immunol. 2004 Apr. 113(4):650-6. [Medline].
Clainche LL, Timsit S, Rigourd V, et al. Asthma and the child below 5 years of age: diagnosis and treatment [in French]. Rev Mal Respir. 2000 Feb. 17(1 Pt 2):213-23. [Medline].
Craig VL, Bigos D, Brilli RJ. Efficacy and safety of continuous albuterol nebulization in children with severe status asthmaticus. Pediatr Emerg Care. 1996 Feb. 12(1):1-5. [Medline].
Crain EF, Mortimer KM, Bauman LJ, et al. Pediatric asthma care in the emergency department: measuring the quality of history-taking and discharge planning. J Asthma. 1999. 36(1):129-38. [Medline].
Csonka P, Mertsola J, Klaukka T, et al. Corticosteroid therapy and need for hospital care in wheezing preschool children. Eur J Clin Pharmacol. 2000 Nov. 56(8):591-6. [Medline].
Darr CD. Asthma and bronchiolitis. Emergency Medicine: Concepts and Clinical Practice. 4th ed. 1998. 1137-45.
Eggleston PA, Wood RA, Rand C, et al. Removal of cockroach allergen from inner-city homes. J Allergy Clin Immunol. 1999 Oct. 104(4 Pt 1):842-6. [Medline].
Farber HJ, Johnson C, Beckerman RC. Young inner-city children visiting the emergency room (ER) for asthma: risk factors and chronic care behaviors. J Asthma. 1998. 35(7):547-52. [Medline].
Garde Garde Jf, Haro E, Sanchez-Lucas C, Garde Noguera J. Antileukotrienes. Their use in pediatrics [in Spanish]. Allergol Immunopathol (Madr). 2000 May-Jun. 28(3):136-43. [Medline].
Gibbs MA, Camargo CA, Rowe BH, Silverman RA. State of the art: therapeutic controversies in severe acute asthma. Acad Emerg Med. 2000 Jul. 7(7):800-15. [Medline].
Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006 May 11. 354(19):1985-97. [Medline]. [Full Text].
Kellner JD, Ohlsson A, Gadomski AM, Wang EE. Efficacy of bronchodilator therapy in bronchiolitis. A meta-analysis. Arch Pediatr Adolesc Med. 1996 Nov. 150(11):1166-72. [Medline].
Kemp JP, Dockhorn RJ, Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6- to 14-year-old children with asthma. J Pediatr. 1998 Sep. 133(3):424-8. [Medline].
Kitch BT, Chew G, Burge HA, et al. Socioeconomic predictors of high allergen levels in homes in the greater Boston area. Environ Health Perspect. 2000 Apr. 108(4):301-7. [Medline].
Le Clainche L, Timsit S, Rigourd V, et al. Asthma in children below 5 years of age: diagnosis and treatment. Rev Mal Respir. 1999 Feb. 16(1):17-27. [Medline].
Newson T, McKenzie S. Cough and asthma in children. Pediatr Ann. 1996 Mar. 25(3):156-8, 161. [Medline].
Qureshi F, Zaritsky A, Lakkis H. Efficacy of nebulized ipratropium in severely asthmatic children. Ann Emerg Med. 1997 Feb. 29(2):205-11. [Medline].
Roback MG, Dreitlein DA. Chest radiograph in the evaluation of first time wheezing episodes: review of current clinical practice and efficacy. Pediatr Emerg Care. 1998 Jun. 14(3):181-4. [Medline].
Rubin BK, Albers GM. Use of anticholinergic bronchodilation in children. Am J Med. 1996 Jan 29. 100(1A):49S-53S. [Medline].
Rudolph CD. Supraesophageal complications of gastroesophageal reflux in children: challenges in diagnosis and treatment. Am J Med. 2003 Aug 18. 115 Suppl 3A:150S-156S. [Medline].
Schreck DM, Babin S. Comparison of racemic albuterol and levalbuterol in the treatment of acute asthma in the ED. Am J Emerg Med. 2005 Nov. 23(7):842-7. [Medline].
Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med. 2000 Sep 7. 343(10):689-94. [Medline].
Spahn JD. Pharmacologic management of pediatric asthma. 1998. 18 (1):165-81.
Stempel DA, Meyer JW, Stanford RH, Yancey SW. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma. J Allergy Clin Immunol. 2001 Jan. 107(1):94-8. [Medline].
Steyer TE, Mallin R, Blair M. Pediatric asthma. Clinics in Family Practice. 2003 Jun. 5:
Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000 Aug 3. 343(5):332-6. [Medline].
Sun HL, Chou MC, Lue KH, et al. The relationship of air pollution to ED visits for asthma differ between children and adults. Am J Emerg Med. 2006 Oct. 24(6):709-13. [Medline].
Walsh-Kelly CM, Kim MK, Hennes HM. Chest radiography in the initial episode of bronchospasm in children: can clinical variables predict pathologic findings?. Ann Emerg Med. 1996 Oct. 28(4):391-5. [Medline].
Welliver RC. Immunologic mechanisms of virus-induced wheezing and asthma. J Pediatr. 1999 Aug. 135(2 Pt 2):14-20. [Medline].
Werk LN, Steinbach S, Adams WG, Bauchner H. Beliefs about diagnosing asthma in young children. Pediatrics. 2000 Mar. 105(3 Pt 1):585-90. [Medline].
Williams JR, Bothner JP, Swanton RD. Delivery of albuterol in a pediatric emergency department. Pediatr Emerg Care. 1996 Aug. 12(4):263-7. [Medline].
Wolfram RW. Asthma. The Clinical Practice of Emergency Medicine. 2nd ed. 1997. 1093-96.
Zeffren BS, Windom HH, Bahna SL. Modern Treatment of Asthma in Children. Mosby Year Book; 1996. Vol 43: 423-68.
|*Includes 95% of white males aged 7-20 years.
Derived and adapted from J Pediatr 1979;95:192-6.